LumiraDx stock falls on MA deal with Roche
| LMDXDelisted Stock | USD 0.42 0.02 4.55% |
Slightly above 61% of LumiraDx's investor base is looking to short. The analysis of current outlook of investing in LumiraDx suggests that many traders are alarmed regarding LumiraDx's prospects. LumiraDx's investing sentiment can be driven by a variety of factors including economic data, LumiraDx's earnings reports, geopolitical events, and overall market trends.
LumiraDx |
LumiraDxs agreement to sell its point-of-care diagnostics platform to Roche for 295M causes a 20 percent premarket loss in its shares. Read more here.
Read at seekingalpha.com
 |
LumiraDx Fundamental Analysis
We analyze LumiraDx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LumiraDx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LumiraDx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
LumiraDx is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
LumiraDx Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with LumiraDx stock to make a market-neutral strategy. Peer analysis of LumiraDx could also be used in its relative valuation, which is a method of valuing LumiraDx by comparing valuation metrics with similar companies.
Peers
LumiraDx Related Equities
| SHC | Sotera Health | 1.65 | ||||
| XGN | Exagen | 1.41 | ||||
| BDSX | Biodesix | 0.68 | ||||
| FONR | Fonar | 0.26 | ||||
| BNR | Burning Rock | 1.22 | ||||
| ENZ | Enzo Biochem | 4.36 | ||||
| SERA | Sera Prognostics | 7.56 | ||||
| DRIO | DarioHealth Corp | 12.50 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in LumiraDx Stock
If you are still planning to invest in LumiraDx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LumiraDx's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |